Most Read Articles
Christina Lau, 5 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.

Carfilzomib-panobinostat combo safe, effective for relapsed/refractory multiple myeloma

04 Feb 2019

The combination of carfilzomib, a second generation proteasome inhibitor, and panobinostat, a histone deacetylase inhibitor, is a safe and effective steroid-sparing regimen for heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), a recent study has found.

Thirty-two RRMM patients (median age 66 years; 53 percent female) participated in the present study, most of whom (84 percent; n=27) were relapsed and refractory to their last line of treatment. The median number of previous lines of treatment was four.

The maximum tolerated doses (MTD) of carfilzomib and panobinostat were 36 mg/m2 and 20 mg, respectively. At these levels, the most common dose-limiting toxicities were grade 4 thrombocytopoenia and a grade 3 increase in creatinine levels.

Other treatment-related adverse events (AE) were also reported. Eleven (37 percent) patients developed at least one serious AE, while any-grade haematological AEs occurred in almost all (97 percent) of the participants. Treatment-emergent, nonhaematological AEs of any grade were similarly highly common (93 percent).

One patient developed a grade 3–4 cardiac AE, while another experienced cardiac arrest, a grade 5 AE. Six patients discontinued the study due to AEs such as thrombocytopoenia, bowel perforation and acute pancreatitis.

In terms of efficacy, the objective response rate (ORR) in the overall study sample was 57 percent. A third of the participants achieved partial response, while 17 percent and 7 percent showed very good partial response (VGPR) and complete response, respectively. The resulting clinical benefit rate was 70 percent. At the MTD, the ORR was 63 percent, and 25 percent of the participants achieved VGPR or better.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 5 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.